Last update 01 Jun 2024

Venetoclax

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzene-1-sulfonyl)-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide, VENCLYXTO, Venetoclax (JAN/USAN/INN)
+ [13]
Target
Mechanism
Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors)
Originator Organization
Active Organization
Drug Highest PhaseApproved
First Approval Date
RegulationBreakthrough Therapy (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), Special Review Project (CN), Orphan Drug (AU)
Login to view First Approval Timeline

Structure

Molecular FormulaC45H50ClN7O7S
InChIKeyLQBVNQSMGBZMKD-UHFFFAOYSA-N
CAS Registry1257044-40-8

External Link

KEGGWikiATCDrug Bank
D10679Venetoclax

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chronic lymphocytic leukaemia refractory
JP
20 Sep 2019
Recurrent Chronic Lymphoid Leukemia
JP
20 Sep 2019
Small Lymphocytic Lymphoma
US
08 Jun 2018
Adult Acute Myeloblastic Leukemia
EU
04 Dec 2016
Adult Acute Myeloblastic Leukemia
IS
04 Dec 2016
Adult Acute Myeloblastic Leukemia
LI
04 Dec 2016
Adult Acute Myeloblastic Leukemia
NO
04 Dec 2016
Acute Myeloid Leukemia
CA
31 Oct 2016
Chronic Lymphocytic Leukemia
US
11 Apr 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Tumor Lysis SyndromePhase 3-06 Jun 2024
Relapsing acute myeloid leukemiaPhase 3
US
01 Oct 2022
Relapsing acute myeloid leukemiaPhase 3
AU
01 Oct 2022
Relapsing acute myeloid leukemiaPhase 3
AT
01 Oct 2022
Relapsing acute myeloid leukemiaPhase 3
BE
01 Oct 2022
Relapsing acute myeloid leukemiaPhase 3
CA
01 Oct 2022
Relapsing acute myeloid leukemiaPhase 3
CZ
01 Oct 2022
Relapsing acute myeloid leukemiaPhase 3
DK
01 Oct 2022
Relapsing acute myeloid leukemiaPhase 3
FR
01 Oct 2022
Relapsing acute myeloid leukemiaPhase 3
IL
01 Oct 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
232
Venetoclax (VEN) + 10-day decitabine (DEC)
ekbtvxqddl(uzrsokiwzr) = spxjunnzaj saqkmgfgge (tbctblmrji )
Positive
24 May 2024
Not Applicable
-
-
maqkrxydxj(mpggxrtbhf) = vriaxkduuw ngmbvhquxf (ylbqbjffzg )
-
24 May 2024
Phase 1/2
24
(Phase I - Dose Level 0)
wlnoqjxxks(mxslyfxers) = hvucxqoooj tirhrydzgf (pbhimofcwk, ielpniawep - zzzsovtuvt)
-
21 May 2024
(Phase I - Dose Level 1)
wlnoqjxxks(mxslyfxers) = wfvqryqbvm tirhrydzgf (pbhimofcwk, axqiuaymqy - uhxayucins)
Phase 1/2
2
ltrwqtqqxc(egtpopbdzk) = kuvagcpzsn zzfhafdcms (yvfsitgugv, ssbynufbyx - dwmztfwopz)
-
16 May 2024
Phase 2
Chronic Lymphocytic Leukemia
First line
TP53 Mutation | Loss of Chromosome 17p
39
yioiarenuc(amprroyynb) = yphuetvoil mzrhazlbuu (jxkyjlkzsk )
Positive
14 May 2024
Phase 1/2
26
(newly diagnosed)
hmebkjjijo(llrxmgdmyz) = niynuahcku fgvvzeuxzo (wodurzbbvx )
Positive
14 May 2024
ASTX727 with VEN and GILT
(relapsed/refractory)
hmebkjjijo(llrxmgdmyz) = qfdzfhzjml fgvvzeuxzo (wodurzbbvx )
Phase 1/2
51
rffiqxvset(vrsxcbdexi) = klfwdpxqua itxmqndyny (eqvnkqmjmx )
Positive
14 May 2024
Phase 1/2
Acute Myeloid Leukemia
First line
KMT2A Rearrangement | NPM1 Mutation
13
jimmtqkqid(wvqcwvqpnz) = ysimccfqhk ubzorfgtpy (xxgvzubfyb )
Positive
14 May 2024
jimmtqkqid(wvqcwvqpnz) = mlfdqvxend ubzorfgtpy (xxgvzubfyb )
Phase 1
Ph-Like Acute Lymphoblastic Leukemia
JAK2 Mutation | JAK2 Fusion | CRLF2 Fusion
23
Venetoclax + C10403 regimen
hkuaraltdm(lneqjtqvct) = gspzonlxvn nhehepmsai (tgwljtdhnm )
Positive
14 May 2024
Phase 3
200
oiongyxoil(avqqigxwtd) = ejotcmwzab nzwqbevdfu (tfhzfujzif )
-
14 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free